Last reviewed · How we verify
FCN-159
FCN-159 is a small molecule that targets the SGLT2 receptor.
FCN-159 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | FCN-159 |
|---|---|
| Sponsor | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, FCN-159 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
Key clinical trials
- Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors (PHASE2)
- Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 (PHASE1, PHASE2)
- FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration (PHASE3)
- An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations (PHASE2)
- FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (PHASE3)
- To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH (PHASE2)
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 (PHASE1, PHASE2)
- MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FCN-159 CI brief — competitive landscape report
- FCN-159 updates RSS · CI watch RSS
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. portfolio CI